RxDoctor Payments Data

Elder Ayala, PA

Medical · van Nuys, CANPI 1801949698

Payments from drug & device makers

$1,958in general payments, 2019–2025

Across 64 payments — averaging $30.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$778
  • GSK$353
  • Amgen$217
  • Exact Sciences$91
  • Pfizer$89
  • Lilly USA, LLC$82
  • plus $347 from 11 others

What the payments were for

  • Food & beverage$1,958100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,958 in reported general payments places this provider in the 70th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$20,376
Medicare patients
70
Services billed
252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin125$120,024
RybelsusSemaglutide60$68,715
JanuviaSitagliptin Phosphate15$19,971
LinzessLinaclotide23$19,406
TradjentaLinagliptin22$18,760
FarxigaDapagliflozin Propanediol15$16,900
Diclofenac Sodium42$10,008
EliquisApixaban13$9,314
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$8,370
JanumetSitagliptin Phos/Metformin Hcl13$6,688
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$2,710
Atorvastatin Calcium235$1,571
Albuterol Sulfate HfaAlbuterol Sulfate51$1,424
Comfort Ez Pen NeedlePen Needle, Diabetic16$1,137
Levothyroxine Sodium84$1,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$778$68,71560 claims
MerckJanuvia, Janumet$48$26,65928 claims
AbbVieLinzess$33$19,40623 claims
PfizerEliquis$89$9,31413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,087 medical providers in California.

Other medical in van Nuys

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →